论文部分内容阅读
放射疗法(RT)治疗小细胞肺癌(SCLC)的效果已被公认,因而近年来被广泛采用。选择性RT 明显减少了脑转移,但作为主要洽疗手段尚有争议.虽 SCLC 对 RT 和化疗(CT)均高度敏感,但其存活期取决于系统的治疗效果。因 RT 优于手术,故已列入 SCLC 的常规治疗。由于系统的 CT 对局部和转移病灶均有效,故已成为 SCLC 的最主要疗法,但远期疗效不佳。经分析长期存活的病例,发现许多患者接受过 RT 和 CT。而后对3400例局限期 SCLC 的78%病人随机分组,进行联合治疗(CMT)。结果,CMT组除副作用稍增加外,其它指标均优于单纯 CT。CMT
The effect of radiation therapy (RT) in the treatment of small cell lung cancer (SCLC) has been recognized and has been widely adopted in recent years. Selective RT significantly reduces brain metastases, but as a primary means of treatment is still controversial. Although SCLC is highly sensitive to RT and chemotherapy (CT), its survival depends on the system’s therapeutic effect. Since RT is superior to surgery, it has been included in the routine treatment of SCLC. Since systemic CT is effective for both local and metastatic lesions, it has become the mainstay of SCLC, but its long-term efficacy is poor. After analyzing long-term survival cases, many patients were found to have received RT and CT. Then 78% of 3400 patients with limited-phase SCLC were randomly assigned to receive combination therapy (CMT). As a result, except for a slight increase in side effects in the CMT group, other indicators were superior to CT alone. CMT